Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia

Psychopharmacology

Volumn 171, Issue 2, 2004, Pages 223-227

  Yasui Furukori, Norio ^a   Kondo, Tsuyoshi ^b   Mihara, Kazuo ^b   Inoue, Yoshimasa ^c   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Dose effect; Drug interaction; Fluvoxamine; Haloperidol

Indexed keywords

BIPERIDEN; DIAZEPAM; FLUNITRAZEPAM; FLUVOXAMINE; HALOPERIDOL; QUAZEPAM; SENNOSIDE;

AKATHISIA; AMNESIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DYSTONIA; EXCITEMENT; FEMALE; GEOMETRY; HALLUCINATION; HEART PALPITATION; HOSTILITY; HUMAN; HYPERKINESIA; HYPERSALIVATION; HYPOKINESIA; HYPOSALIVATION; MALE; MEDICAL ASSESSMENT; MICTURITION DISORDER; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RATING SCALE; REDUCTION; RESTLESSNESS; RIGIDITY; SCHIZOPHRENIA; SCORING SYSTEM; SELF ESTEEM; SIDE EFFECT; SOMNOLENCE; TENSION; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLUVOXAMINE; HALOPERIDOL; HUMANS; INPATIENTS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 1642537724     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1567-y     Document Type: Article

References (27)

1. Armstrong SC, Stephans JR (1997) Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. J Clin Psychiatry 58:499
2. Bech P, Kastrup M, Rafaelsen OJ (1986) Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl 326:1-37
3. Caccia S (2000) Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 38:393-414
4. Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JA, Berecz R, Duran M, Benitez J (1999) Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 19:494-499
5. Christensen M, Tybring G, Mihara K, Yasui-Furukori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L (2002) Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 71:141-152
6. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14:340-343
7. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L (2001) Interaction of olanzapine with fluvoxamine. Psychopharmacology 155:219-220
8. Fabrazzo M, La Pia S, Monteleone P, Mennella R, Esposito G, Pinto A, Maj M (2000) Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time-and dose-dependent manner. J Clin Psychopharmacol 20:708-710
9. Fang J, Baker GB, Silverstone PH, Coutts RT (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17:227-233
10. Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35-39
11. Heeringa M, Beurskens R, Schouten W, Verduijn MM (1999) Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 21:243-244
12. Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Hartter S, Modai I, Ritsner M, Silver H (2002) Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22:502-506
13. Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y (1989) Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J Chromatogr 495:227-234
14. Kudo S, Odomi M (1998) Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 54:253-259
15. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, Bark N (1995) Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 28:22-31
16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1-100
17. Markowitz JS, Gill HS, Lavia M, Brewerton TD, DeVane CL (1996) Fluvoxamine-clozapine dose-dependent interaction. Can J Psychiatry 41:670-671
18. Santamaria B, Perez M, Montero D, Madurga M, de Abajo FJ (2002) Use of antipsychotic agents in Spain through 1985-2000. Eur Psychiatry 17:471-476
19. Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283-304
20. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M (2000) Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 15:257-261
21. Tsang MW, Shader RI, Greenblatt DJ (1994) Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 14:159-162
22. Van Putten T, Marder SR, Mintz J, Poland RE (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 149:500-505
23. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Rojdmark S (2000) Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 56:123-127
24. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131
25. Weigmann H, Gerek S, Zeisig A, Muller M, Hartter S, Hiemke C (2001) Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 23:410-413
26. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism Clin Pharmacol Ther 59:514-519
27. Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A, Kaneko S, Inoue Y (1999) Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol 19:149-154